Last update 20 Mar 2025

68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel)

Overview

Basic Info

Drug Type
Radiolabeled antibody, Diagnostic radiopharmaceuticals
Synonyms-
Target
Action
inhibitors
Mechanism
CD206 inhibitors(Macrophage mannose receptor 1 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AtherosclerosisPhase 2
Belgium
26 Jan 2021
Cardiac sarcoidosisPhase 2
Belgium
26 Jan 2021
Carotid StenosisPhase 2
Belgium
26 Jan 2021
Head and Neck NeoplasmsPhase 2
Belgium
26 Jan 2021
Hodgkin's LymphomaPhase 2
Belgium
26 Jan 2021
Lymphohistiocytosis, HemophagocyticPhase 2
Belgium
26 Jan 2021
Non-Hodgkin LymphomaPhase 2
Belgium
26 Jan 2021
Breast CancerPhase 2
Belgium
05 Nov 2019
Malignant Solid NeoplasmPhase 2
Belgium
05 Nov 2019
Melanoma, Cutaneous MalignantPhase 2
Belgium
05 Nov 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free